Biopharma Co. Maxygen Fears Amgen Might Sue
Biopharmaceutical company Maxygen Inc. has warned that Amgen Inc. might look to file a patent infringement suit against the company when it starts seeking regulatory approval for MAXY-G34, its treatment for...To view the full article, register now.
Already a subscriber? Click here to view full article